New York, April 25, 2023 (GLOBE NEWSWIRE) -- According to Market.us, The global biopharmaceutical CMO market size generated around USD 16.2 billion in revenue in 2022 and is expected to be worth around USD 51.5 billion by 2032, at CAGR of over 12.6% during 2022-2032. The biopharmaceutical CMO comes from several sources, which include non-mammalian and mammalian. The biopharmaceutical CMO facilities involve fill and finish operations, manufacturing analytical and packaging studies. The biopharmaceutical market is expected to see significant development during the forecast period. The major type of biopharmaceutical CMO products includes biologics and biosimilars. Also, biologics produce a wide range of products from human, animal, or microbial sources as biological treatments. Merger and acquisitions help CMOs offers bioprocess combination devices for their customers, making CMO more valuable and attractive time-to-time for the rapid growth of the biopharmaceutical CMO market.
Market.us has identified key trends, drivers, and challenges in the market, which will help clients improve their strategies to stay ahead of their competitors. - View a PDF sample report @ https://market.us/report/biopharmaceutical-cmo-market/request-sample/
Key Takeaway:
- By Product Type, the biologics segment generated a revenue share of 84% in 2022.
- By Service, the Manufacturing segment has dominated the market, growing at a CAGR of 46.10% over the forecast period.
- In 2022, North America dominated the market with the highest revenue share of 34.2%.
- Europe held a 26% revenue share in 2022.
- Asia-Pacific will grow at the highest CAGR from 2023-2032.
Factors affecting the growth of the Biopharmaceutical CMO Market?
- Increase in the geriatric population: Due to the increase in the number of chronic disease patients, there is also an increase in the demand for biopharmaceutical CMOs in the market which will help to drive the market growth.
- Demand for Novel Therapeutics: The increase in the demand for new advanced therapeutics with the increased incidences of chronic diseases and the increase in the demand for biosimilar products is expected to drive the market's growth.
- High-cost services: The high cost of biopharmaceutical CMO services and data security is also responsible for the growth of the biopharmaceutical CMO market.
To understand how our report can bring a difference to your business strategy, Inquire about a brochure at https://market.us/report/biopharmaceutical-cmo-market/#inquiry
Top Trends in Global Biopharmaceutical CMO Market
The increase in demand for mammalian cell culture and microbial fermentation facilities helps to increase demand for microbial fermentation, and mammalian cell culture service is increasing in industries. It focuses on biologics development based on a procedure such as monoclonal antibodies and recombinant protein. The advanced development will help enhance the market growth by introducing new drugs and motivating innovation in biopharmaceutical manufacturing. Biopharmaceutical CMO continuously focuses on innovative products and consistently moves toward union through mergers & acquisitions, joint ventures, and collaborative partnerships. Such trends are witnessed in this market, boosting the demand for these products. The market price contains associated properties sold by the facility supplier or within the service offering. Only properties and services traded between entities or sold to end consumers are included.
Market Growth
The growing adoption of advanced technology with increases in healthcare expenditure, rising R&D activities, and an increase in drug development and drug discovery procedures helps to drive the growth of the market. Also, increasing demand for Contract manufacturing organizations is anticipated to offer lucrative opportunities for the expansion of the biopharmaceutical CMO market.
Regional Analysis:
North America is the most dominating region in the biopharmaceutical CMO market, holding the largest share during the forecast period due to the presence of many CMO manufacturing facilities, with several small-scale CMOs entering this region. Various small and medium-sized pharma producers are contracting pharmaceutical production to the CMOs due to a lack of investments. The increasing geriatric population, high patient volumes, rising per capita incomes, and growing awareness among individuals are driving the need for enhancing the healthcare industries in these nations. Asia Pacific is driving the surge in outsourcing due to lower labor and operations expenses. India is expected to show significant progress due to the large volume of large molecule creation in this region. India's large-molecule manufacturing is also expected to boost its economy.
To know about the regional trends and drivers that will have an impact on the market - Request a sample report!
Scope of the Report
| Report Attribute | Details |
| Market Value (2022) | US$ 16.2 Billion |
| Market Size (2032) | US$ 51.5 Billion |
| CAGR (from 2022 to 2032) | 12.6% |
| North America Revenue Share | 34.2% |
| Europe Revenue Share | 26% |
| Historic Period | 2016 to 2022 |
| Base Year | 2022 |
| Forecast Year | 2023 to 2032 |
Market Drivers
The market will continually grow as biotechnology and pharmaceutical companies increase their investments in contract manufacturing and development services. The biopharmaceutical manufacturing market is estimated to register the highest growth, expanding small CMOs during the forecast period. The increasing awareness about biologics is simultaneously increasing the demand for fill&Finish services. The rising demand is due to the growing number of biologics pipelines anticipated to grow during the forecast period. The increasing number of robust pipelines will help to increase demand for operating devices. Many CMOs has been investing and providing facilities for increasing cost production in the market. The CMOs use automation and innovative technologies at their plants to improve their project throughput and product quality capabilities. It has driven large molecule manufacturers' interest in the CMOs to meet the growing demand for biologicsThe demand for tests in diagnosis treatment is also growing significantly due to the presence of a high number of applications in biopharmaceutical CMO in the healthcare sector.
Market Restraints
The biopharmaceutical CMO market is increasing the cost of devices to improve profit due to high-profit margins but due to high-profit margins as compared to other manufacturing industries in the biopharmaceutical CMO market. In addition, manufacturing operating devices requires high costs as an initial investment in additional devices to start biomanufacturing at a higher rate. These factors may restrict the market growth. Furthermore, the limited use of contracting well-established biopharmaceutical companies also hampered the market expansion.
Market Opportunities
The biopharmaceutical CMO market is also boosted due to growing healthcare facilities in several developing countries. The biopharmaceutical CMOs are affecting innovative growth prospects. Expanding R&D efforts and investment is critical to developing market growth. Regional allowances, new product improvement, industry cooperation, assignment development, and consolidations and acquisitions are other development strategies to acquire a competitive advantage in the worldwide market. The rapidly growing geriatric population, high patient volumes, and growing awareness among individuals are driving the need for expanding healthcare companies in these nations. However, the governments in these economies are increasing their funding to enhance healthcare infrastructure & facilities. Due to the increasing demand for biopharmaceutical CMOs in healthcare businesses, the increased funding in this sector is expected to offer growth opportunities in the market.
Immediate Delivery Available | Buy This Premium Research Report@ https://market.us/purchase-report/?report_id=96860
Report Segmentation of the Biopharmaceutical CMO Market
Product Type Insight
The biopharmaceutical CMO market is segmented based on product type into biologics and biosimilars. Biologics held the largest segment in the global Biopharmaceutical CMO market. The biologics again sub-categorized into monoclonal antibodies, recombinant proteins, vaccines, antisense, RNAi & molecular therapy, and others. The increase in demand for this segment is due to its safe and effective use. The increasing investment, technological advancement, and increasing interest of pharma developers in biologics help with the rise in demand for this biopharmaceutical market. The biosimilar product is anticipated to grow with high cost as they provide affordable solutions and alternative biologics. Less accuracy and safety problems in this segment may hamper its growth.
Service Type Insight
Based on service type, the market is segmented into manufacturing, analytical & Q.C. studies, fill & finish operations, and packaging. The manufacturing segment is the most dominating segment, with the highest market share during the projection period. Due to the increase in the rate of contract manufacturing, this segment held the largest shares. This manufacturing segment is subcategorized into two types upstream and downstream processing. Downstream processing is a complex procedure that requires advanced technologies based on novel manufacturing tools. Therefore, the downstream processing segment is anticipated to hold the largest shares during the forecast period. The fill & finish service segment show significant growth during the projection period. This segment supports the growth by increasing demand for operating devices in the biopharmaceutical CMO market.
Source Type Insight
Based on the source, the market is segmented into mammalian and Non-mammalian. The mammalian segment is the most dominating segment in the biopharmaceutical CMO market. It is used for the development of new vaccines and the detection of diseases. On the other hand, the non-mammalian segment is anticipated to raise significant shares due to its use in the production of bio-therapeutics such as enzymes, cytokines, hormones, and antibodies.
If you want to get a better understanding of the report, you can access a PDF sample, which includes the complete table of contents, list of exhibits, selected illustrations, and example pages @ https://market.us/report/biopharmaceutical-cmo-market/request-sample/
Market Segmentation
Based on Type
- Biologics
- Biosimilars
Based on Service
- Manufacturing
- Fill & Finish Operations
- Analytical & C. studies
- Packaging
Based on Source
- Mammalian
- Non-Mammalian
By Geography
- North America
- The US
- Canada
- Mexico
- Western Europe
- Germany
- France
- The UK
- Spain
- Italy
- Portugal
- Ireland
- Austria
- Switzerland
- Benelux
- Nordic
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- The Czech Republic
- Greece
- Rest of Eastern Europe
- APAC
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- Indonesia
- Malaysia
- Philippines
- Singapore
- Thailand
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Colombia
- Chile
- Argentina
- Costa Rica
- Rest of Latin America
- Middle East & Africa
- Algeria
- Egypt
- Israel
- Kuwait
- Nigeria
- Saudi Arabia
- South Africa
- Turkey
- United Arab Emirates
- Rest of MEA
Competitive Landscape
The competitive landscape of the market has also been examined in this report. Some of the major players include:
- Lonza
- JRS Pharma
- Samsung Biologics
- CMC Biologics
- TOYOBO Co. Ltd.
- FUJIFILM Biosynth Biotechnologies
- Wuxi Biologics
- Pantheon
- PRA Health Science
- LabCorp
- Other key players
Recent Development of the Biopharmaceutical CMO Market
April-2021: Thermos Fisher Scientific declared to gain PPD Inc., a top worldwide supplier of drug fabricating and clinical research administration, to the biotech business. Expanding their production capacity and client service would support their market position.
Browse More Related Reports:
- Biopharmaceuticals Market size is expected to be worth around USD 566 billion by 2032 from USD 262.5 billion in 2022, growing at a CAGR of 8.2%.
- Pharmaceutical Filtration Market was worth USD 27,079.69 million with a CAGR value of 14.6%.
- Nanopharmaceuticals Market was valued at US$ 67.5 Billion and expected to grow US$ 259.2 Billion in 2032.
- Radiopharmaceuticals market was valued at US$ 4.5 Billion and expected to grow US$ 10.3 Billion in 2032.
- Pharmaceutical excipients market size is expected to be worth around USD 11.8 bn by 2032 from USD 6.6 bn in 2022, growing at a CAGR of 5.8%.
About Us:
Market.US (Powered by Prudour Pvt Ltd) specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicated market research report-providing firm. Market.US provides customization to suit any specific or unique requirement and tailor-makes reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons.
Follow Us on LinkedIn | Facebook | Twitter
Our Blog:
